GoAI
Get started
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp.

AVR

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$8.98

−$0.27 · -2.92%

Aug 21, 4:00 PM ET

AVR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

26

Expensive

Momentum

70

Gaining

Sentiment

60

Mixed

Risk resilience

58

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Wayne Geoffrey Paterson
Listed since
Dec 13, 2024
Employees
174

Market position

Day range

Current $8.98

52-week range

Current $8.98

Open
$9.365
Previous close
$9.25
Volume
567.15K
0.51× average
Average volume
1.11M
Average daily volume
Market cap
873.14M USD
Beta
0.73
Market reference 1
50-day average
$9.106
-1.38% below average
200-day average
$6.6449
+35.14% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
173.89M USD
P/E (TTM)
-3.25×
P/B (TTM)
3.48×
P/S (TTM)
389.45×
EV / EBITDA
-1.88×
Earnings yield
-51.11%
Free cash flow yield
-43.30%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
36.98%
Operating margin
-4738.36%
Net margin
-4619.67%
Return on equity
101230.11%
Return on assets
-409.38%
Return on invested capital
-4256.30%

Financial health

Debt / equity
0.01×
Current ratio
0.73×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends544%-1444%-3431%-5418%Gross margin, FY2021: 32.68%Gross margin, FY2022: 9.32%Gross margin, FY2023: 32.06%Gross margin, FY2024: 46.84%Gross margin, FY2025: -16.57%Operating margin, FY2021: -289.18%Operating margin, FY2022: -972.11%Operating margin, FY2023: -1760.26%Operating margin, FY2024: -2899.45%Operating margin, FY2025: -4908.21%Net margin, FY2021: -294.50%Net margin, FY2022: -954.91%Net margin, FY2023: -1682.81%Net margin, FY2024: -2822.46%Net margin, FY2025: -4921.28%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 32.68%. Gross margin FY2022 9.32%. Gross margin FY2023 32.06%. Gross margin FY2024 46.84%. Gross margin FY2025 -16.57%. Operating margin FY2021 -289.18%. Operating margin FY2022 -972.11%. Operating margin FY2023 -1760.26%. Operating margin FY2024 -2899.45%. Operating margin FY2025 -4908.21%. Net margin FY2021 -294.50%. Net margin FY2022 -954.91%. Net margin FY2023 -1682.81%. Net margin FY2024 -2822.46%. Net margin FY2025 -4921.28%.

Income trends

Revenue

1.91M USD-29.23%

Operating income

−93.89M USD-19.81%

Net income

−94.14M USD-23.40%
Income trends across reported periods15.83M USD−24.16M USD−64.15M USD−104.14M USDRevenue, FY2021: 5.83M USDRevenue, FY2022: 3.2M USDRevenue, FY2023: 2.73M USDRevenue, FY2024: 2.7M USDRevenue, FY2025: 1.91M USDOperating income, FY2021: −16.86M USDOperating income, FY2022: −31.11M USDOperating income, FY2023: −48.14M USDOperating income, FY2024: −78.37M USDOperating income, FY2025: −93.89M USDNet income, FY2021: −17.17M USDNet income, FY2022: −30.56M USDNet income, FY2023: −46.02M USDNet income, FY2024: −76.29M USDNet income, FY2025: −94.14M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.83M USD. Revenue FY2022 3.2M USD. Revenue FY2023 2.73M USD. Revenue FY2024 2.7M USD. Revenue FY2025 1.91M USD. Operating income FY2021 −16.86M USD. Operating income FY2022 −31.11M USD. Operating income FY2023 −48.14M USD. Operating income FY2024 −78.37M USD. Operating income FY2025 −93.89M USD. Net income FY2021 −17.17M USD. Net income FY2022 −30.56M USD. Net income FY2023 −46.02M USD. Net income FY2024 −76.29M USD. Net income FY2025 −94.14M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.91M USD2.7M USD2.73M USD3.2M USD5.83M USD
Cost of goods sold2.23M USD1.44M USD1.86M USD2.9M USD3.93M USD
Gross profit−317K USD1.27M USD876.8K USD298.38K USD1.91M USD
Research and development69.12M USD51.45M USD31.02M USD17.59M USD9.99M USD
Selling, general, and administrative24.46M USD—17.05M USD15.21M USD9.14M USD
Operating expenses93.58M USD79.64M USD49.02M USD31.41M USD18.77M USD
Interest income709K USD—428.06K USD210.38K USD68.55K USD
Interest expense73K USD82K USD67.09K USD648.71K USD1.03M USD
Depreciation and amortization1.66M USD1.51M USD1.16M USD774.08K USD640.09K USD
Operating income−93.89M USD−78.37M USD−48.14M USD−31.11M USD−16.86M USD
Net income−94.14M USD−76.29M USD−46.02M USD−30.56M USD−17.17M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
13%
1 beat, 7 misses, 0 met estimates
Average EPS surprise
-42.23%
8 comparable reports
Latest EPS result
-0.3
Estimate -0.21 · Miss by 44.72%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.18-0.38-0.58-0.78Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -0.52, estimate -0.565, surprise +7.96%, Beat. Q2 2025, reported May 13, 2025: actual -0.61, estimate -0.533, surprise -14.38%, Miss. Q3 2025, reported Aug 12, 2025: actual -0.58, estimate -0.545, surprise -6.42%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.62, estimate -0.542, surprise -14.32%, Miss. Q1 2026, reported Mar 11, 2026: actual -0.74, estimate -0.271, surprise -173.23%, Miss. Q2 2026, reported May 12, 2026: actual -0.28, estimate -0.271, surprise -3.39%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.3, estimate -0.207, surprise -44.72%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.313, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.95M2.03M1.1M170KQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 500K USD, estimate 733.33K USD, surprise -31.82%, Miss. Q2 2025, reported May 13, 2025: actual 556K USD, estimate 466.67K USD, surprise +19.14%, Beat. Q3 2025, reported Aug 12, 2025: actual 618K USD, estimate 400K USD, surprise +54.50%, Beat. Q4 2025, reported Nov 10, 2025: actual 429K USD, estimate 400K USD, surprise +7.25%, Beat. Q1 2026, reported Mar 11, 2026: actual 303K USD, estimate 200K USD, surprise +51.50%, Beat. Q2 2026, reported May 12, 2026: actual 494K USD, estimate 766.67K USD, surprise -35.57%, Miss. Q3 2026, reported Aug 11, 2026: actual 1.01M USD, estimate 1.5M USD, surprise -32.73%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate 2.75M USD, surprise —, Comparison unavailable.

AVR news

defenseworld.net

Assenagon Asset Management S.A. Invests $6.35 Million in Anteris Technologies Global Corp. $AVR

Assenagon Asset Management S.A. bought a new stake in Anteris Technologies Global Corp. (NASDAQ: AVR) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange…

Read source
globenewswire.com

Anteris Technologies Announces Results for the Second Quarter of 2026

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing,…

Read source
defenseworld.net

Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Sells 174,721 Shares

Anteris Technologies Global Corp. (NASDAQ: AVR - Get Free Report) major shareholder L1 Capital Pty Ltd sold 174,721 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was sold at an…

Read source
proactiveinvestors.com

Pennon returns to profit after water bill hikes

Pennon Group PLC (LSE:PNN, OTC:PEGRY) returned to the black in its latest financial as higher regulatory allowances and increased water consumption boosted...

Read source
globenewswire.com

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance…

Read source

AVR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding AVR

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
19.48M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
7.09M
Weight
0.05%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.91M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.59M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
2.61M
Weight
0.17%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Invesco Dorsey Wright SmallCap Momentum ETF logoInvesco Dorsey Wright SmallCap Momentum ETFDWAS
Market value
1.66M
Weight
0.38%
AUM
434.69M USD
Expense ratio
0.60%
Price / 1D
$114.27+1.10%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.35M
Weight
0.02%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
State Street SPDR S&P Health Care Equipment ETF logoState Street SPDR S&P Health Care Equipment ETFXHE
Market value
1.09M
Weight
0.62%
AUM
176.38M USD
Expense ratio
0.35%
Price / 1D
$96.68+1.37%

Continue in GoAI

Research AVR

research.disclaimer